Tirzepatide Microdose

Microdose tirzepatide refers to using tirzepatide, the active ingredient in Zepbound and Mounjaro, at a weekly dose below the lowest FDA-approved starting dose of 2.5 mg. In everyday practice, this most often means somewhere between 0.5 mg and 2.0 mg per week, though there is no consensus clinical definition and no randomized controlled trial has tested a true microdose as a primary endpoint (Cedars-Sinai, Hackensack Meridian Health, STAT News).

Microdosing sits below the FDA-approved starting dose. The term originates in patient and telehealth communities, not in regulatory guidance or peer-reviewed medicine. As Dr. Amanda Velazquez, obesity-medicine director at Cedars-Sinai, put it: "Microdosing is not a medical term. We don't have any evidence that low-dose, intermittent use of GLP-1s provides meaningful or sustained weight loss or broader health benefits" (Cedars-Sinai).

What the evidence does show is a clear dose-response relationship. In the SURMOUNT-1 trial, tirzepatide produced average body-weight losses of 15.0% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg over 72 weeks, compared with 3.1% for placebo (Jastreboff et al., NEJM 2022). No trial has tested weekly doses below 2.5 mg for weight loss, so any efficacy claims about true microdoses are extrapolations, not evidence.

Google's AI Overview and academic-medical-center commentary identify three main groups of patients who explore subtherapeutic tirzepatide dosing. Each is a decision made in conversation with a licensed provider, not a self-titration.

1. Side-effect tolerance. Gastrointestinal adverse events (nausea, vomiting, constipation, diarrhea) scale with dose in the SURMOUNT program. Some patients and providers use very slow titration or lower maintenance doses to stay within a tolerable range (Jastreboff et al., NEJM 2022). A 2025 Diabetes Care commentary describes physicians using multidose pens for fractional titration below the FDA-approved starting dose specifically for GI tolerability (Komé et al., 2025).
2. Weight maintenance after significant loss. The SURMOUNT-4 trial found that patients who continued tirzepatide 15 mg lost an additional 5.5% of body weight over 52 weeks, while those switched to placebo regained approximately 14.0% (Aronne et al., JAMA 2024). Some patients explore a lower maintenance dose as a middle path, though SURMOUNT-4 tested continuation vs. full discontinuation, not a reduced-dose arm.
3. Metabolic and non-weight goals. Tirzepatide's cardio-metabolic benefits, including improvements in blood pressure, lipids, and glycemic control, were demonstrated at 5, 10, and 15 mg in the SURMOUNT program (Jastreboff et al., NEJM 2022). Long-term cardiovascular outcome data at these doses are still emerging. Benefits at weekly doses below 2.5 mg have not been tested in a randomized trial.

Here is the honest state of published evidence on subtherapeutic tirzepatide as of 2026:

• SURMOUNT-1 (tirzepatide 5/10/15 mg, 72 weeks): mean body-weight loss of −15.0%, −19.5%, and −22.5% vs. −3.1% for placebo. Titration ran through 2.5, 5, 7.5, 10, 12.5, and 15 mg. The trial did not report outcomes for doses held below 2.5 mg (NEJM 2022).
• SURMOUNT-3 (tirzepatide + intensive lifestyle intervention, 84 weeks): after a 12-week lifestyle lead-in, tirzepatide produced an additional 21.1% body-weight loss vs. 3.3% with placebo, for total mean losses of 26.6% and 3.8%, respectively (Wadden et al., Nat Med 2023).
• SURMOUNT-4 (maintenance): after 36 weeks of open-label titration to a maximum-tolerated dose (10 or 15 mg), patients continuing that dose lost an additional 5.5% over 52 weeks; patients switched to placebo regained approximately 14.0% (Aronne et al., JAMA 2024; registration NCT04660643).
• Komé et al., Diabetes Care 2025: commentary describing GLP-1 and GLP-1/GIP multidose-pen fractional titration below the FDA-approved starting dose for GI tolerability, drug transitions, or cost. The authors explicitly note the practice is not endorsed by the manufacturer and lacks controlled-trial validation (PMC12964163).
• Wu, Cengiz, Lawley, Obesity 2025: case series and pharmacokinetic model suggesting that reduced-frequency dosing (biweekly instead of weekly) may preserve a substantial fraction of weight-loss efficacy for maintenance. This is a frequency change, not a dose change, and is preliminary (PMC12210098).
• FDA Zepbound label: approved dose escalation is 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. The label does not describe or approve maintenance below 2.5 mg (FDA Zepbound label).

What the evidence does not show: No randomized trial has demonstrated meaningful weight loss, cardiovascular benefit, or metabolic benefit from weekly tirzepatide doses below 2.5 mg. Any efficacy claim about true microdoses is extrapolation from the dose-response curve, not direct evidence.

Lower dose is not the same as lower risk. The FDA boxed warning and contraindications for tirzepatide apply at any dose (FDA Zepbound label). Physicians at Cedars-Sinai and Hackensack Meridian have emphasized this repeatedly: microdose does not mean microrisk (Cedars-Sinai, Hackensack Meridian Health).

Contraindications that apply regardless of dose:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity to tirzepatide
• Pregnancy or breastfeeding
• Active pancreatitis or a history of severe pancreatitis
• Severe gastroparesis

Adverse events that can occur at any dose: nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder disease, acute kidney injury from dehydration, injection-site reactions, and rare cases of pancreatitis. Compounded tirzepatide adds additional considerations because it is not FDA-approved as a finished drug product; safety depends on the compounding pharmacy following USP 797 sterile-compounding standards.

Provider oversight is the point. A licensed-provider evaluation reviews your medical history, current medications, laboratory values where appropriate, and goals before any protocol is set. Ongoing check-ins allow the provider to adjust or discontinue treatment if side effects, contraindications, or lack of benefit emerge. Microdose protocols should never be self-titrated based on internet dosing charts.

Through Madison Meds, compounded tirzepatide is available in a range of protocols, including subtherapeutic ("microdose") formulations, after a licensed-provider evaluation by an independent network of US-licensed providers, with the medication dispensed by a US-licensed compounding pharmacy. Program pricing starts from $199 your first month and $249 per month thereafter for the microdose program, which reflects the smaller compounded dose.

Our licensed-provider network can discuss whether a lower-dose starter or maintenance protocol may be appropriate based on your individual health profile, prior GLP-1 or GLP-1/GIP experience, and goals. Because subtherapeutic dosing sits below the FDA-approved starting dose and lacks randomized trial support, providers will explain the trade-offs honestly: the appeal (slower onset, reduced GI side-effect reports, lower cost) and the limits (no efficacy guarantee, no proven cardio-metabolic benefit at microdose levels, ongoing safety monitoring still required).

Every prescription is written for an individual patient. Compounded tirzepatide is not FDA-approved as a finished drug product, and Madison Meds does not represent it as equivalent to Zepbound or Mounjaro. Outcomes are individual, and results vary from person to person.